Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 927,017 shares of the company's stock after acquiring an additional 90,822 shares during the quarter. Dimensional Fund Advisors LP owned about 0.92% of Day One Biopharmaceuticals worth $11,745,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of the stock. FMR LLC boosted its stake in Day One Biopharmaceuticals by 73.9% during the 4th quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after purchasing an additional 5,475,087 shares in the last quarter. Franklin Resources Inc. grew its stake in Day One Biopharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock valued at $49,197,000 after buying an additional 13,320 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Day One Biopharmaceuticals by 17.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock valued at $44,219,000 after buying an additional 507,398 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Day One Biopharmaceuticals by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 1,462,982 shares of the company's stock valued at $18,541,000 after buying an additional 30,285 shares during the period. Finally, Marshall Wace LLP bought a new stake in Day One Biopharmaceuticals in the 4th quarter worth about $13,909,000. Hedge funds and other institutional investors own 87.95% of the company's stock.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeremy Bender sold 12,048 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. This trade represents a 8.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,064 shares of company stock valued at $251,925 in the last 90 days. Company insiders own 6.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Wedbush reaffirmed an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Finally, Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $30.57.

Day One Biopharmaceuticals Trading Down 3.8%

NASDAQ DAWN traded down $0.25 during trading on Tuesday, hitting $6.33. 1,970,557 shares of the company traded hands, compared to its average volume of 1,085,771. Day One Biopharmaceuticals, Inc. has a 12 month low of $6.10 and a 12 month high of $17.14. The company has a market capitalization of $641.62 million, a P/E ratio of -6.15 and a beta of -1.24. The business has a fifty day simple moving average of $7.64 and a 200 day simple moving average of $11.00.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. Equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.